Featured Research

from universities, journals, and other organizations

Green tea compound shows promise for tackling cancer

Date:
August 22, 2012
Source:
University of Strathclyde
Summary:
Green tea compound shows promise for tackling cancer

A compound found in green tea could be a weapon in treatments for tackling cancer, according to newly published research at the University of Strathclyde.

The extract, known as epigallocatechin gallate, has been known to have preventative anti-cancer properties but fails to reach tumours when delivered by conventional intravenous administration.

However, in initial laboratory tests at the Universities of Strathclyde and Glasgow, researchers used an approach which allowed the treatment to be delivered specifically to the tumours after intravenous administration. Nearly two-thirds of the tumours it was delivered to either shrank or disappeared within one month and the treatment displayed no side effects to normal tissues.

The tests are thought to be the first time that this type of treatment has made cancerous tumours shrink or vanish.

In the tests, on two different types of skin cancer, 40% of both types of tumour vanished, while 30% of one and 20% of another shrank. A further 10% of one of the types were stabilised.

The researchers encapsulated the green tea extract in vesicles that also carried transferrin, a plasma protein which transports iron through the blood. Receptors for transferrin are found in large amounts in many cancers.

Dr Christine Dufθs, a senior lecturer at the Strathclyde Institute of Pharmacy and Biomedical Sciences, led the research. She said: "These are very encouraging results which we hope could pave the way for new and effective cancer treatments.

"When we used our method, the green tea extract reduced the size of many of the tumours every day, in some cases removing them altogether. By contrast, the extract had no effect at all when it was delivered by other means, as every one of these tumours continued to grow.

"This research could open doors to new treatments for what is still one of the biggest killer diseases in many countries."

The research paper has been published in the journal Nanomedicine. Imaging equipment used in the research was funded by a grant from the Wellcome Trust.

The research links to Advanced Science and Technology, one of the research themes at Strathclyde's Technology and Innovation Centre, a world-class facility uniting academic and industrial partners in seeking innovative research solutions, job creation and business development.


Story Source:

The above story is based on materials provided by University of Strathclyde. Note: Materials may be edited for content and length.


Journal Reference:

  1. Fanny Lemariι, Chun Wai Chang, David R Blatchford, Rumelo Amor, Greg Norris, Laurence Tetley, Gail McConnell, Christine Dufθs. Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration. Nanomedicine, 2012; DOI: 10.2217/nnm.12.83

Cite This Page:

University of Strathclyde. "Green tea compound shows promise for tackling cancer." ScienceDaily. ScienceDaily, 22 August 2012. <www.sciencedaily.com/releases/2012/08/120822071433.htm>.
University of Strathclyde. (2012, August 22). Green tea compound shows promise for tackling cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/08/120822071433.htm
University of Strathclyde. "Green tea compound shows promise for tackling cancer." ScienceDaily. www.sciencedaily.com/releases/2012/08/120822071433.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins